Back to Search
Start Over
Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes.
- Source :
-
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Jun 17; Vol. 109 (7), pp. 1883-1890. - Publication Year :
- 2024
-
Abstract
- Context: Low-density lipoprotein cholesterol (LDL-C)-lowering therapy is considerably important in preventing cardiovascular disease (CVD) among patients with diabetes. Studies comparing CVD, stroke, and mortality outcomes of low- or moderate-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy in patients with diabetes remain lacking.<br />Objective: This study compared the primary prevention effect of myocardial infarction (MI), stroke, and all-cause death between combination therapy of low- or moderate-intensity statins and ezetimibe and high-intensity statin monotherapy in patients with diabetes using the Korean National Health Insurance claims database.<br />Methods: Patients aged ≥20 years with type 2 diabetes and dyslipidemia were enrolled. The combination therapy of low- or moderate-intensity statin and ezetimibe was compared with high-intensity statin monotherapy after a propensity score-matched analysis. The incidence of composite outcomes consisting of MI, stroke, and all-cause death and each component were analyzed.<br />Results: In moderate-intensity statin therapy with ezetimibe combination therapy, LDL-C (74 ± 37.9 mg/dL vs 80.8 ± 38.8 mg/dL, P < .001) and the incidence of composite outcomes were lower (hazard ratio 0.85, 95% CI 0.74-0.98) than those in high-intensity statin monotherapy. Meanwhile, no significant difference was observed in the LDL-C levels and composite outcomes between low-intensity statins with ezetimibe combination therapy and high-intensity statin monotherapy.<br />Conclusion: Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C-lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Treatment Outcome
Republic of Korea epidemiology
Cholesterol, LDL blood
Myocardial Infarction epidemiology
Myocardial Infarction prevention & control
Stroke prevention & control
Stroke epidemiology
Adult
Dyslipidemias drug therapy
Dyslipidemias epidemiology
Dyslipidemias blood
Retrospective Studies
Cardiovascular Diseases prevention & control
Cardiovascular Diseases epidemiology
Cardiovascular Diseases etiology
Cardiovascular Diseases mortality
Diabetes Mellitus, Type 2 drug therapy
Diabetes Mellitus, Type 2 complications
Diabetes Mellitus, Type 2 blood
Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Drug Therapy, Combination
Ezetimibe therapeutic use
Ezetimibe administration & dosage
Anticholesteremic Agents administration & dosage
Anticholesteremic Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1945-7197
- Volume :
- 109
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- The Journal of clinical endocrinology and metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 38175670
- Full Text :
- https://doi.org/10.1210/clinem/dgad714